Down-regulation of HSP60 Suppresses the Proliferation of Glioblastoma Cells via the ROS/AMPK/mTOR Pathway

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Tang, Haiping ^a   Li, Jin ^a   Liu, Xiaohui ^a   Wang, Guihuai ^b   Luo, Minkui ^c   Deng, Haiteng ^a  

^a TSINGHUA UNIVERSITY   (China)

^b BEIJING TSINGHUA CHANGGUNG HOSPITAL   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; CHAPERONIN 60; HEAT SHOCK PROTEIN 90; HSPD1 PROTEIN, HUMAN; LIPID; MITOCHONDRIAL PROTEIN; MTOR PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; ROTENONE; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

BRAIN TUMOR; CELL PROLIFERATION; CHEMISTRY; DISEASE EXACERBATION; DOWN REGULATION; ELECTRON TRANSPORT; GENE EXPRESSION REGULATION; GENE SILENCING; GLIOBLASTOMA; HEK293 CELL LINE; HUMAN; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ADENYLATE KINASE; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHAPERONIN 60; DISEASE PROGRESSION; DOWN-REGULATION; ELECTRON TRANSPORT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HEK293 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIPIDS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; OXIDATIVE STRESS; PROTEIN BIOSYNTHESIS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; ROTENONE; TOR SERINE-THREONINE KINASES;

EID: 84975473712     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28388     Document Type: Article

References (53)

1. Legler, J. M. et al. Cancer surveillance series: brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl. Cancer Inst. 91, 1382-1390 (1999).
2. Cloughesy, T. F., Cavenee, W. K. & Mischel, P. S. Glioblastoma: from molecular pathology to targeted treatment. Annu. Rev. Pathol. 9, 1-25 (2014).
3. Dunn, G. P. et al. Emerging insights into the molecular and cellular basis of glioblastoma. Gene Dev. 26, 756-784 (2012).
4. Masui, K., Cloughesy, T. F. & Mischel, P. S. Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropath. Appl. Neuro. 38, 271-291 (2012).
5. Mrugala, M. M. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov. Med. 15, 221-230 (2013).
6. Stewart, L. A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018 (2002).
7. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
8. Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
9. Cloughesy, T. F. et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLos Med. 5, e8 (2008).
10. Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214-226 (2008).
11. Lianos, G. D. et al. The role of heat shock proteins in cancer. Cancer Lett. 360, 114-118 (2015).
12. Bukau, B. & Horwich, A. L. The Hsp70 and Hsp60 chaperone machines. Cell 92, 351-366 (1998).
13. Fersht, A. R. & Daggett, V. Protein folding and unfolding at atomic resolution. Cell 108, 573-582 (2002).
14. White, G. W. N. et al. Simulation and experiment conspire to reveal cryptic intermediates and a slide from the nucleation condensation to framework mechanism of folding. J. Mol. Biol. 350, 757-775 (2005).
15. Arya, R., Mallik, M. & Lakhotia, S. C. Heat shock genes - integrating cell survival and death. J. Biosci. 32, 595-610 (2007).
16. Samali, A., Cai, J., Zhivotovsky, B., Jones, D. P. & Orrenius, S. Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. EMBO J. 18, 2040-2048 (1999).
17. Kirchhoff, S. R., Gupta, S. & Knowlton, A. A. Cytosolic heat shock protein 60, apoptosis, and myocardial injury. Circulation 105, 2899-2904 (2002).
18. Cappello, F., Di Stefano, A., D'Anna, S. E., Donner, C. F. & Zummo, G. Immunopositivity of heat shock protein 60 as a biomarker of bronchial carcinogenesis. Lancet Oncol. 6, 816-816 (2005).
19. Cappello, F. et al. HSP60 and HSP10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer 107, 2417-2424 (2006).
20. Lebret, T. et al. Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 98, 970-977 (2003).
21. Kamishima, T. et al. Carcinosarcoma of the urinary bladder: expression of epithelial markers and different expression of heat shock proteins between epithelial and sarcomatous elements. Pathol. Int. 47, 166-173 (1997).
22. Hwang, Y. J. et al. Expression of Heat Shock Protein 60 kDa Is Upregulated in Cervical Cancer. Yonsei Med. J. 50, 399-406 (2009).
23. Castilla, C. et al. Immunohistochemical Expression of Hsp60 Correlates With Tumor Progression and Hormone Resistance in Prostate Cancer. Urology 76, 1017.e1-1017.e6 (2010).
24. Hamrita, B. et al. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). Clin. Chim. Acta 393, 95-102 (2008).
25. Ghosh, J. C., Dohi, T., Kang, B. H. & Altieri, D. C. Hsp60 regulation of tumor cell apoptosis. J. Biol. Chem. 283, 5188-5194 (2008).
26. Sabharwal, S. S. & Schumacker, P. T. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat. Rev. Cancer 14, 709-721 (2014).
27. Krishan, S., Richardson, D. R. & Sahni, S. Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol. Pharmacol. 87, 363-377 (2015).
28. Roy, L. D. et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30, 1449-1459 (2011).
29. Xu, L., Chow, K. K. H., Lim, M. & Li, G. Current Vaccine Trials in Glioblastoma: A Review. J. Immunol Res. (2014).
30. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 352, 987-996 (2005).
31. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
32. Ghosh, J. C., Siegelin, M. D., Dohi, T. & Altieri, D. C. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res. 70, 8988-8993 (2010).
33. Carroll, J. et al. Bovine complex I is a complex of 45 different subunits. J. Biol. Chem. 281, 32724-32727 (2006).
34. Sabharwal, S. S. & Schumacker, P. T. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat. Rev. Cancer 14, 709-721 (2014).
35. 2 Signaling. Antioxid. Redox Sign. 14, 459-468 (2011).
36. Sharma, L. K. et al. Mitochondrial respiratory complex I dysfunction promotes tumorigenesis through ROS alteration and AKT activation. Hum. Mol. Genet. 20, 4605-4616 (2011).
37. Hardie, D. G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 774-785 (2007).
38. Steinberg, G. R. & Kemp, B. E. AMPK in Health and Disease. Physiol. Rev. 89, 1025-1078 (2009).
39. Srivastava, R. A. et al. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J. Lipid Res. 53, 2490-2514 (2012).
40. Ruderman, N. B., Carling, D., Prentki, M. & Cacicedo, J. M. AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest. 123, 2764-2772 (2013).
41. Shaw, R. J. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol. (Oxf) 196, 65-80 (2009).
42. Inoki, K., Li, Y., Xu, T. & Guan, K. L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Gene Dev. 17, 1829-1834 (2003).
43. Dibble, C. C. & Manning, B. D. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 15, 555-564 (2013).
44. Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214-226 (2008).
45. Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471-484 (2006).
46. Holz, M. K., Ballif, B. A., Gygi, S. P. & Blenis, J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123, 569-580 (2005).
47. Haghighat, A., Mader, S., Pause, A. & Sonenberg, N. Repression of Cap-Dependent Translation by 4E-Binding Protein 1:Competition with P220 for Binding to Eukaryotic Initiation Factor-4E. EMBO J. 14, 5701-5709 (1995).
48. Gingras, A. C. et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Gene Dev. 13, 1422-1437 (1999).
49. Hardie, D. G. & Pan, D. A. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans. 30, 1064-1070 (2002).
50. Li, Y. et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13, 376-388 (2011).
51. Tiedemann, R. E. et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res. 72, 757-768 (2012).
52. Gu, L. et al. Functional Characterization of Sirtuin-like Protein in Mycobacterium smegmatis. J. Proteome Res. 14, 4441-4449 (2015).
53. Bligh, E. G. & Dyer, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917 (1959).